Phagos Secures €25 Million in Series A Funding to Fight Bacterial Infections

Paris-based biotech company Phagos has successfully raised €25 million in a Series A funding round, four years post its establishment. The investment round was co-led by CapAgro, Hoxton Ventures, CapHorn, and Demeter, with additional support from Acurio Ventures. The funding boost is aimed at advancing Phagos' innovative treatments targeting bacterial diseases.